Last reviewed · How we verify
hypromellose 0.3%
Hypromellose is a cellulose-based polymer that forms a protective lubricating film on the ocular surface to relieve dry eye symptoms.
Hypromellose is a cellulose-based polymer that forms a protective lubricating film on the ocular surface to relieve dry eye symptoms. Used for Dry eye disease / Keratoconjunctivitis sicca, Ocular irritation and discomfort.
At a glance
| Generic name | hypromellose 0.3% |
|---|---|
| Also known as | GenTeal® |
| Sponsor | Allergan |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Hypromellose is a synthetic cellulose derivative that acts as an artificial tear substitute. When applied topically to the eye, it increases tear film viscosity and stability, providing lubrication and protection to the cornea and conjunctiva. This helps reduce friction and irritation associated with dry eye disease by maintaining moisture on the ocular surface.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
- Ocular irritation and discomfort
Common side effects
- Blurred vision
- Eye irritation
- Mild stinging or burning
Key clinical trials
- Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease (NA)
- Nd:YAG Laser Vitreolysis for Symptomatic Vitreous Floaters (NA)
- Comparative Efficacy of Lipid Based Artificial Tears vs Aqueous Based Artificial Tears in Managing EDE (NA)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Acupoint Therapy Device for Dry Eye (NA)
- Evaluation of Performance and Safety of Eye Drops With Hydroxypropyl-methylcellulose and Inositol in Drye Eye Disease (NA)
- Dual-Polymer Hydroxypropyl Guar-and Hyaluronic Acid Lubricants in Rheumatoid Arthritis (PHASE4)
- Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |